Compare BHST & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHST | VRCA |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | Canada | United States |
| Employees | 87 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.2M | 87.5M |
| IPO Year | N/A | 2018 |
| Metric | BHST | VRCA |
|---|---|---|
| Price | $4.25 | $5.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $12.00 | ★ $17.00 |
| AVG Volume (30 Days) | 21.9K | ★ 124.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $116.40 | $372.93 |
| Revenue Next Year | $55.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.10 | $0.39 |
| 52 Week High | $12.80 | $9.82 |
| Indicator | BHST | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 36.75 | 34.76 |
| Support Level | N/A | $3.96 |
| Resistance Level | $5.02 | $6.44 |
| Average True Range (ATR) | 0.28 | 0.40 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 16.74 | 16.97 |
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.